Osteoporosis International

, Volume 20, Issue 7, pp 1101–1106

Monitoring strontium ranelate therapy in patients with osteoporosis


    • University of British Columbia
  • J. D. Adachi
    • Department of Medicine, St. Joseph’s HealthcareMcMaster University
  • R. G. Josse
    • Osteoporosis Centre, St. Michael’s HospitalUniversity of Toronto
  • D. O. Slosman
    • Institut de Médecine Nucléaire, 20 Chemin BeausoleilClinique Générale Beaulieu

DOI: 10.1007/s00198-009-0886-1

Cite this article as:
Kendler, D.L., Adachi, J.D., Josse, R.G. et al. Osteoporos Int (2009) 20: 1101. doi:10.1007/s00198-009-0886-1



The purpose of this study was to review the monitoring of strontium ranelate osteoporosis therapy.


The method used in this study was comprehensive literature review with clinical perspectives.


Changes in bone turnover markers (BTM) or bone mineral density (BMD) have been documented in osteoporosis clinical trials. However, neither BMD nor BTM changes fully explain the observed fracture risk reduction in treated patients. If changes in BMD or BTM on therapy would be easily discernable in individual patients, and were strongly associated with fracture risk reduction, monitoring individuals would be more useful. BMD changes in patients on strontium ranelate are of a greater magnitude and hence can be easily determined in an individual patient. In addition, there exists a better correlation between fracture risk reduction and increases in BMD.


The strong correlation between measured BMD increases and fracture risk reduction in patients on strontium ranelate therapy will be of clinical benefit to physicians wishing to evaluate both treatment persistence and fracture risk reduction.


Bone mineral densityBone turnover markersMonitoring osteoporosis therapyStrontium ranelate

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009